Oral administration of Ag suppresses Ag-induced allergic conjunctivitis in mice: Critical timing and dose of Ag

British Journal of Ophthalmology

Volumn 97, Issue 4, 2013, Pages 492-497

  Ishida, Waka ^a   Fukuda, Ken ^a   Harada, Yosuke ^a   Sumi, Tamaki ^a   Taguchi, Osamu ^a   Tsuda, Masayuki ^a   Yagita, Hideo ^b   Fukushima, Atsuki ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; BASILIXIMAB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA;

AG INDUCED ALLERGIC CONJUNCTIVITIS; AG-INDUCED ALLERGIC CONJUNCTIVITIS; ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; BLOOD; CONJUNCTIVA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SENSITIZATION; SPLEEN; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ALLERGENS; ANIMALS; ANTIBODIES, NEUTRALIZING; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; OVALBUMIN; T-LYMPHOCYTES, REGULATORY; THYMECTOMY; TIME FACTORS;

EID: 84875227420     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302639     Document Type: Article

References (26)

1. Friedlaender MH. Immunologic aspects of diseases of the eye. JAMA 1992;268:2869-73.
2. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother 2002;3:541-53. (Pubitemid 34520864)
3. Valenta R, Campana R, Marth K, et al. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012;272:144-57.
4. Weiner HL. Oral tolerance. Proc Natl Acad Sci USA 1994;91:10762-5. (Pubitemid 24349564)
5. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809-37. (Pubitemid 24140432)
6. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006;13:143-57. (Pubitemid 44950033)
7. Brozek JL, Terracciano L, Hsu J, et al. Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis. Clin Exp Allergy 2012;42:363-74.
8. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2006;117:1047-53.
9. Pajno GB, Finegold I. SIT beyond respiratory diseases. Ann Allergy Asthma Immunol 2011;107:395-400.
10. Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67: 302-11.
11. Koizumi T, Abe T. Induction of oral tolerance to experimental allergic conjunctivitis in rats. Nihon Ganka Gakkai Zasshi 1995;99:515-20.
12. Zemann B, Schwaerzler C, Griot-Wenk M, et al. Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF-beta expression and prevents allergy in adult life. J Allergy Clin Immunol 2003;111:1069-75. (Pubitemid 36570868)
13. Marchant A, Bruyns C, Vandenabeele P, et al. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994;24:1167-71.
14. Dasch JR, Pace DR, Waegell W, et al. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 1989;142:1536-41. (Pubitemid 19086319)
15. Shoji J, Sakimoto T, Muromoto K, et al. Comparison of topical dexamethasone and topical FK506 treatment for the experimental allergic conjunctivitis model in BALB/c mice. Jpn J Ophthalmol 2005;49:205-10. (Pubitemid 40880060)
16. Magone MT, Chan CC, Rizzo LV, et al. A novel murine model of allergic conjunctivitis. Clin Immunol Immunopathol 1998;87:75-84. (Pubitemid 28194165)
17. Haneda K, Sano K, Tamura G, et al. TGF-beta induced by oral tolerance ameliorates experimental tracheal eosinophilia. J Immunol 1997;159:4484-90. (Pubitemid 127470609)
18. Sumi T, Fukushima A, Fukuda K, et al. Thymus-derived CD4+ CD25+ T cells suppress the development of murine allergic conjunctivitis. Int Arch Allergy Immunol 2007;143:276-81. (Pubitemid 47067039)
19. Fukushima A, Yamaguchi T, Azuma M, et al. Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. Br J Ophthalmol 2006;90:1040-5. (Pubitemid 44140189)
20. Faria AM, Maron R, Ficker SM, et al. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin- 10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun 2003;20:135-45. (Pubitemid 36349072)
21. Min SY, Hwang SY, Park KS, et al. Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther 2004;6:213-19.
22. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890-8. (Pubitemid 28096086)
23. Fukushima A, Sumi T, Fukuda K, et al. Interleukin 10 and transforming growth factor beta contribute to the development of experimentally induced allergic conjunctivitis in mice during the effector phase. Br J Ophthalmol 2006;90:1535-41. (Pubitemid 44862577)
24. Wessel F, Chartier A, Meunier JP, et al. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial. Clin Drug Investig. 2012;32:451-63.
25. Takaiwa F. Seed-based oral vaccines as allergen-specific immunotherapies. Hum Vaccin 2011;7:357-66.
26. Takagi H, Hiroi T, Yang L, et al. A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc Natl Acad Sci USA 2005;102:17525-30. (Pubitemid 41740899)